Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood Am Soc Hematol. 2016;127:2375–2390.
   Google Scholar
• Mottok A, Hung SS, Chavez EA, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood. 2019;134(10):802–813.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019 Dec 26;134(26):2369–2382.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Döring C, Brune V, et al. Analyzing primary hodgkin and reed-sternberg cells to capture the molecular and cellular pathogenesis of classical hodgkin lymphoma. Blood. 2012;120(23):4609–4620.
   PubMed Web of Science ®Google Scholar
• Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical hodgkin lymphoma. Blood. 2018 May 31;131(22):2413–2425.
   PubMed Web of Science ®Google Scholar
• Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary hodgkin and reed-sternberg cells. Blood. 2015 Feb 12;125(7):1061–1072.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277.
   PubMed Web of Science ®Google Scholar
• Twa DDW, Steidl C. Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leukemia Lymphoma. 2015;56(8):2239–2250.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J clin oncol. 2016 Aug 10;34(23):2690–2697.
   PubMed Web of Science ®Google Scholar
• Twa DDW, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–2065.
   PubMed Web of Science ®Google Scholar
• Aoki T, Izutsu K, Suzuki R, et al. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica. 2014;99(12):1817–1825.
   PubMed Web of Science ®Google Scholar
• Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology. 2017;2017(1):298–303.
   PubMedGoogle Scholar
• Camus V. R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: a 10-YEARS Experience of Lysa Centers. blood:ASH. 2020.
   Google Scholar
• Vardhana S, Hamlin PA, Yang J, et al. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018 Oct 1;24(10):2133–2138.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol,  2016 Nov 1; 34(31):3733–3739.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144.
   PubMed Web of Science ®Google Scholar
• Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med. 1980 Apr;68(4):509–514.
   PubMed Web of Science ®Google Scholar
• Perrone T, Frizzera G, Rosai J, et al. Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol. 1986 Mar;10(3):176–191.
   PubMed Web of Science ®Google Scholar
• Möller P, Lämmler B, Eberlein-Gonska M, et al. Primary mediastinal clear cell lymphoma. Virchows Archiv A. 1986;409(1):79–92. Available from: https://doi.org/10.1007/BF00705408
   Web of Science ®Google Scholar
• Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology. 1986 Apr; 10(4):379–390.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994 Sep 1;84(5):1361–1392.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011 May 12;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des lymphomes de l’Adulte”) study. Am J Surg Pathol. 1996 Jul;20(7):877–888.
   PubMed Web of Science ®Google Scholar
• Lekovic D, Miljic P, Mihaljevic B, et al. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res. 2010 Dec;126(6):477–480.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016 May;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Gaulard P, Maouche-Chrétien L, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999 Nov 15;94(10):3567–3575.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002 Nov;15(11):1172–1180.
   PubMed Web of Science ®Google Scholar
• Takaba H, Takayanagi H. The mechanisms of T cell selection in the thymus. Trends Immunol. 2017;38(11):805–816.
   PubMed Web of Science ®Google Scholar
• Gies V, Guffroy A, Danion F, et al. B cells differentiate in human thymus and express AIRE. J Allergy Clin Immunol. 2017;139(3):1049–1052. e12.
   PubMed Web of Science ®Google Scholar
• Yamano T, Nedjic J, Hinterberger M, et al. Thymic B cells are licensed to present self antigens for central T cell tolerance induction. Immunity. 2015 Jun;42(6):1048–1061.
   PubMed Web of Science ®Google Scholar
• Malpeli G, Barbi S, Moore PS, et al. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. Haematologica. 2004 Sep;89(9):1091–1099.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to hodgkin lymphoma. J Exp Med. 2003;198(6):851–862.
   PubMed Web of Science ®Google Scholar
• TF B MB, D B SB, MJ S MB, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 2001;30(4):393–401.
   Web of Science ®Google Scholar
• Tanaka Y, Maeshima AM, Nomoto J, et al. Expression pattern of PD-L1 and PD-L2 in classical hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol. 2018;100(5):511–517.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical hodgkin lymphoma. Blood. 2003;102(12):3871–3879.
   PubMed Web of Science ®Google Scholar
• Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011 Mar 17;471(7338):377–383.
   PubMed Web of Science ®Google Scholar
• Roberts RA, Wright G, Rosenwald AR, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006 Jul 1;108(1):311–318.
   PubMed Web of Science ®Google Scholar
• Diepstra A, Van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by hodgkin reed-sternberg cells is an independent prognostic factor in classical hodgkin’s lymphoma. J Clin Oncol , 2007 Jul; 25(21):3101–3108.
   PubMed Web of Science ®Google Scholar
• Mottok A, Woolcock B, Chan FC, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13(7):1418–1431.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Advani RH, Redd RA, et al. Classical hodgkin lymphoma with reduced β2M/MHC class i expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res. 2016 Nov 1;4(11):910–916.
   PubMed Web of Science ®Google Scholar
• Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and hodgkin lymphoma. Nat Genet. 2014;46(4):329–335.
   PubMed Web of Science ®Google Scholar
• Viganò E, Gunawardana J, Mottok A, et al. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. Blood. 2018 May;131(18):2036–2046.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Chong L, Takata K, et al. Gene expression profiling of gray zone lymphoma. Blood Adv. 2020 Jun 9;4(11):2523–2535.
   PubMed Web of Science ®Google Scholar
• Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical hodgkin lymphoma. Nat Med. 2020 Sep 1;26(9):1468–1479.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Michail M, Papageorgiou S, et al. Identification of very low‐risk subgroups of patients with primary mediastinal large B‐Cell lymphoma treated with R‐CHOP. The Oncologist. 2021 Jul;26(7):597-609. DOI: 10.1002/onco.13789.Epub2021Jun17.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v116–25.
   PubMedGoogle Scholar
• Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v91-v102.
   Google Scholar
• Meignan M, Barrington S, Itti E, et al. Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014 Jan;55(1):31–37.
   PubMed Web of Science ®Google Scholar
• Lazarovici J, Terroir M, Arfi-Rouche J, et al. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2018–2024.
   PubMed Web of Science ®Google Scholar
• Ceriani L, Martelli M, Gospodarowicz MK, et al. Positron emission tomography/computed tomography assessment after immunochemotherapy and irradiation using the lugano classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2017 01;97(1):42–49.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?. Blood. 2015 Jan 1;125(1):33–39.
   PubMed Web of Science ®Google Scholar
• Melani C, Advani R, Roschewski M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica. 2018 Aug;103(8):1337–1344.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Papageorgiou SG, Angelopoulou MK, et al. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Ann Hematol [Internet]. 2021 Feb 1 [ cited 2021 Jun 11]. Available from: http://link.springer.com/10.1007/s00277-021-04421–2
   Google Scholar
• Vassilakopoulos TP, Pangalis GA, Chatziioannou S, et al. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia. 2016 Jan;30(1):238–242.
   PubMed Web of Science ®Google Scholar
• Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(9):2171–2179.
   PubMed Web of Science ®Google Scholar
• Camus V, Stamatoullas A, Mareschal S, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical hodgkin lymphoma. Haematologica. 2016;101(9):1094–1101.
   PubMed Web of Science ®Google Scholar
• Massoud M, Koscielny S, Lapusan S, et al. Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. Leuk Lymphoma. 2008 Jan; 49(8):1510–1515.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-Adjusted EPOCH-Rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013 Apr 11;368(15):1408–1416.
   PubMed Web of Science ®Google Scholar
• Gleeson M, Hawkes EA, Cunningham D, et al. R-CHOP in primary mediastinal B-cell lymphoma (PMBL): results from the UK NCRI R-CHOP 14 v 21 trial. Blood. 2015 Dec 3;126(23):2689.
   Google Scholar
• Hayden A, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET adapted approach. Blood [Internet]. 2020 Jun 30 [ cited 2020 Nov 2]. Available from: https://ashpublications.org/blood/article/doi/10.1182/blood.2019004296/461229/Outcome-of-Primary-Mediastinal-Large-Bcell
   Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011 Nov;378(9806):1858–1867.
   PubMed Web of Science ®Google Scholar
• Stepanishyna Y. DA-EPOCH-R VS R-CHOP in Patients with Primary Mediastinal Large B-Cell Lymphoma: results of Prospective Randomized Ukrainian Multicenter Study. Blood. 2020.
   Google Scholar
• Xu L-M, Fang H, Wang W-H, et al. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy. Leuk Lymphoma. 2013 Aug;54(8):1684–1690.
   PubMed Web of Science ®Google Scholar
• Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood. 2018 23; 132(8):782–790.
   PubMed Web of Science ®Google Scholar
• Xu L-M, Li Y-X, Fang H, et al. Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1289–1295.
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Marzolini MAV, Barrington SF, et al. The management of primary mediastinal B‐cell lymphoma: a British society for haematology good practice paper. Br J Haematol. 2019 May;185(3):402–409.
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Dabaja B, Ahmed MA, et al. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):113–121.
   PubMed Web of Science ®Google Scholar
• Hayden A, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET adapted approach. Blood. 2020 Jun 30. DOI:10.1182/blood.2019004296.
   Web of Science ®Google Scholar
• Tai WM, Quah D, Yap SP, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive asian patients. Leuk Lymphoma. 2011 Apr;52(4):604–612.
   PubMed Web of Science ®Google Scholar
• Chan EHL, Koh LP, Lee J, et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med. 2019;8(10):4626–4632.
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Kleinstern G, Orevi M, et al. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy. Cancer Chemother Pharmacol. 2016;77(5):1053–1060.
   PubMed Web of Science ®Google Scholar
• Messmer M, Tsai H-L, Varadhan R, et al. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2019;60(5):1261–1265.
   PubMed Web of Science ®Google Scholar
• Malenda A, Kołkowska‐Leśniak A, Puła B, et al. Outcomes of treatment with dose‐adjusted EPOCH‐R or R‐CHOP in primary mediastinal large B‐cell lymphoma. Eur J Haematol. 2020 Jan;104(1):59–66.
   PubMed Web of Science ®Google Scholar
• Held G. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: a subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). Journal of Clinical Oncology. 2020;38(15_suppl):8041–8041. DOI: 10.1200/JCO.2020.38.15_suppl.8041.
   Google Scholar
• Cairoli H, Grillo G, Tedeschi A, et al. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant. 2002 Mar;29(6):473–477.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial sloan kettering from 1980 to 1999. Br J Haematol. 2005 Sep;130(5):691–699.
   PubMed Web of Science ®Google Scholar
• Liu X, Deng T, Guo X, et al. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. Hematology. 2017 Jun;22(5):258–264.
   PubMed Web of Science ®Google Scholar
• Avivi I, Boumendil A, Finel H, et al. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(8):1001–1009.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Ghesquieres H, Obéric L, et al. Obinutuzumab versus rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood [Internet]. 2020 Nov 19 [ cited 2020 Dec 7]. Available from: https://ashpublications.org/blood/article/doi/10.1182/blood.2020008750/474212/Obinutuzumab-versus-Rituximab-in-young-patients
   Google Scholar
• Trneny M, Polgarova K, Janikova A, et al. IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY?. Hematol Oncol. 2019 Jun;37:267–268.
   Google Scholar
• Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of hodgkin lymphoma: a report from the childhood cancer survivor study. Blood. 2011 Feb 10;117(6):1806–1816.
   PubMed Web of Science ®Google Scholar
• Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose–volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010 Mar;76(3):S77–85.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following hodgkin’s disease: a 20-year follow-up study. J clin oncol. 1994 Feb;12(2):312–325.
   PubMedGoogle Scholar
• De Bruin ML, Sparidans J, Van’t Veer MB, et al. Breast cancer risk in female survivors of hodgkin’s lymphoma: lower risk after smaller radiation volumes. J clin oncol. 2009 Sep 10;27(26):4239–4246.
   PubMed Web of Science ®Google Scholar
• Nielsen KM, Offersen BV, Nielsen HM, et al. Short and long term radiation induced cardiovascular disease in patients with cancer. Clin Cardiol. 2017 Apr;40(4):255–261.
   PubMed Web of Science ®Google Scholar
• Hawkes EA. Can PET eradicate irradiation in PMBCL?. Blood. 2020 Dec 10; 136(24):2725–2726.
   PubMed Web of Science ®Google Scholar
• Aoki T, Shimada K, Suzuki R, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J. 2015 Dec;5(12):e372–e372.
   PubMedGoogle Scholar
• Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008 Jan;49(7):1329–1336.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Dickson M, Kewalramani T, et al. Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: outcome with ICE-based treatment. Blood. 2006 Nov 16;108(11):3057.
   Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997 Apr;15(4):1646–1653.
   PubMed Web of Science ®Google Scholar
• Vardhana S, Hamlin PA, Yang J, et al. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018 Oct;24(10):2133–2138.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998 Jan 15;91(2):717–723.
   PubMed Web of Science ®Google Scholar
• Saini N. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood. 2020. abstract 3331.
   Google Scholar
• Bohers E, Viailly P-J, Becker S, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018 01;8(8):74.
   PubMedGoogle Scholar
• Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017 Apr 6;129(14):1947–1957.
   PubMed Web of Science ®Google Scholar
• Pang D, Jiang X, Huang L, et al. Ctdna Monitoring in Predicting Relapse of Primary Mediastinal B-Cell Lymphoma. Blood. 2020. Abstract 1229.
   Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. American Journal of Clinical Oncology: Cancer Clinical Trials. 2016;39(1):98–106. Lippincott Williams and Wilkins.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee HT, Shin W, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016 Oct 31;7(1):1–10.
   Google Scholar
• Tan S, Zhang H, Chai Y, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017 Feb 6;8(1):1–10.
   PubMedGoogle Scholar
• Hutchins B, Starling GC, McCoy MA, et al. Biophysical and immunological characterization and in vivo pharmacokinetics and toxicology in nonhuman primates of the anti-PD-1 antibody pembrolizumab. Mol Cancer Ther. 2020 Jun 1;19(6):1298–1307.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588.
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase i KEYNOTE-001 study. J Clin Oncol. 2019 Oct 1;37(28):2518–2527.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267–270.
   PubMed Web of Science ®Google Scholar
• Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer. 2017 May 16;5(1):1–9.
   PubMedGoogle Scholar
• Zinzani PL. Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. ASH: Blood. 2020. 136 (Supplement 1): 42–43.
   Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J clin oncol. 2014;32:3059–3067. American Society of Clinical Oncology.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J clin oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL | FDA [internet]. [ cited 2020 Dec 3]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-treatment-relapsed-or-refractory-pmbcl
   Google Scholar
• de‐la‐Fuente C, Nuñez F, Cortés‐Romera M, et al. Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement. Hematol Oncol. Hematol Oncol. 2020 Dec 28. DOI: 10.1002/hon.2836.
   Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J clin oncol. 2018 Apr 1;36(10):942–950.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep 1;17(9):1283–1294.
   PubMed Web of Science ®Google Scholar
• Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol. 2003 Jan 15;170(2):711–718.
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004 Jul 15;173(2):945–954.
   PubMed Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Apr 1;116(7):1767–1775.
   PubMed Web of Science ®Google Scholar
• Cha E, Klinger M, Hou Y, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014 May 28;6(238). DOI: 10.1126/scitranslmed.3008211.
   PubMed Web of Science ®Google Scholar
• Reinke S, Bröckelmann PJ, Iaccarino I, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic hodgkin lymphoma treated with anti-PD1. Blood. 2020 Oct 28;136(25):2851–2863.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, et al. CCR Drug Updates FDA Approval Summary: pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019 Jul 1;25(13):3753–3758.
   Google Scholar
• De Claro RA, McGinn K, Kwitkowski V, et al. U.S. food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012 Nov 1;18(21):5845–5849.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV hodgkin’s lymphoma. N Engl J Med. 2018 Jan 25;378(4):331–344.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory hodgkin lymphoma. Blood. 2018 Mar 15;131(11):1183–1194.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkmate 436 study. J clin oncol. 2019;37(33):3081–3089.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leukemia Lymphoma. 2008 Jul;49(7):1329–1336.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16):2328–2330.
   PubMed Web of Science ®Google Scholar
• Cao AT, Law C-L, Gardai SJ, et al. Abstract 5588: brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo. Cancer Res. 2017;5588. American Association for Cancer Research (AACR). 2017;77(13).
   Web of Science ®Google Scholar
• Heiser RA, Grogan BM, Manlove LS, et al. Abstract 1789: CD30 + T regulatory cells, but not CD30 + CD8 T cells, are impaired following brentuximab vedotin treatment in vitro and in vivo. American Association for Cancer Research (AACR). 2018; 78(13):1789.
   Google Scholar
• FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma | FDA [internet]. [ cited 2020 Dec 22]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma
   Google Scholar
• Chiappella A. Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting. Blood: ASH. 2020;136(1):12–13.
   Google Scholar
• Berinstein N. Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: the Spirel Study. Blood: ASH. 2020136(1):16.
   Google Scholar
• Ramakrishnan A. Phase 1 Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T Cell Therapy, with Pembrolizumab in Patients with Relapsed/ Refractory (r/r) DLBCL. Blood: ASH; 2020.
   Google Scholar
• Jaeger U, Worel N, McGuirk JP, et al. Portia: a phase 1b study evaluating safety and efficacy of tisagenlecleucel and pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2019 Nov 13;134(Supplement_1):5325.
   Google Scholar
• Chong EA, Svoboda J, Dwivedy Nasta S, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas. Blood. 2018 Nov 29;132(Supplement 1):4198.
   Google Scholar
• Witzig TE, Maddocks KJ, De Vos S, et al. Phase 1/2 trial of acalabrutinib plus pembrolizumab (pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). J clin oncol. 2019 May 20;37(15_suppl):7519.
   Google Scholar
• Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020 Jun 1;189(6):1119–1126.
   PubMed Web of Science ®Google Scholar
• Huang G, Huang J, Zhang Z, et al. Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review. J Int Med Res. 2020 Aug 1;48(8). DOI: 10.1177/0300060520945075.
   Web of Science ®Google Scholar
• Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 Feb;180(4):534–544.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Westin JR, Fowler NH, et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study. JCO. 2017 May 20;35(15_suppl):7519.
   Google Scholar
• Armand P, Chen Y-B, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 Jul 4;134(1):22–9
   Google Scholar